{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:09:57Z","timestamp":1788826197217,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41431-026-02020-1","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T21:29:37Z","timestamp":1769722177000},"page":"1319-1326","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Results of a multigene panel testing approach targeting patients with suspected genetic predisposition to pancreatic ductal adenocarcinoma"],"prefix":"10.1038","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-9082","authenticated-orcid":false,"given":"Bruno","family":"Buecher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Warcoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukhshona","family":"Abdullazoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lia","family":"Le Guillevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9146-9346","authenticated-orcid":false,"given":"Chrystelle","family":"Colas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Golmard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"2020_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/gutjnl-2019-319352","volume":"69","author":"M Goggins","year":"2020","unstructured":"Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the international Cancer of the Pancreas Screening (CAPS) consortium. Gut. 2020;69:7\u201317.","journal-title":"Gut"},{"key":"2020_CR2","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1002\/humu.24491","volume":"43","author":"R Leman","year":"2022","unstructured":"Leman R, Parfait B, Vidaud D, Girodon E, Pacot L, Le Gac G, et al. SPiP: splicing Prediction Pipeline, a machine learning tool for massive detection of exonic and intronic variant effects on mRNA splicing. Hum Mutat. 2022;43:2308\u201323.","journal-title":"Hum Mutat"},{"key":"2020_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cell.2018.12.015","volume":"176","author":"K Jaganathan","year":"2019","unstructured":"Jaganathan K, Panagiotopoulou SK, McRae JF, Darbandi SF, Knowles D, Li YI, et al. Predicting splicing from primary sequence with deep learning. Cell. 2019;176:535\u201348.","journal-title":"Cell"},{"key":"2020_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"2020_CR5","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","volume":"34","author":"T Conroy","year":"2023","unstructured":"Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, O\u2019Reilly EM, et al. ESMO Guidelines Committee. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:987\u20131002.","journal-title":"Ann Oncol"},{"key":"2020_CR6","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.6004\/jnccn.2023.0051","volume":"21","author":"MB Daly","year":"2023","unstructured":"Daly MB, Pal T, Maxwell KN, Churpek J, Kohlmann W, AlHilli Z, et al. NCCN guidelines insights: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2024. J Natl Compr Canc Netw. 2023;21:1000\u201310.","journal-title":"J Natl Compr Canc Netw"},{"key":"2020_CR7","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","volume":"28","author":"T Frebourg","year":"2020","unstructured":"Frebourg T, Bajalica Lagercrantz S, Oliveira C, Magenheim R, Evans DG. European Reference Network GENTURIS. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet. 2020;28:1379\u201386.","journal-title":"Eur J Hum Genet"},{"key":"2020_CR8","doi-asserted-by":"publisher","first-page":"e00414","DOI":"10.14309\/ctg.0000000000000414","volume":"12","author":"PLS Uson Jr","year":"2021","unstructured":"Uson PLS Jr, Samadder NJ, Riegert-Johnson D, Boardman L, Borad MJ, Ahn D, et al. Clinical impact of pathogenic germline variants in pancreatic cancer: results from a multicenter, prospective, universal genetic testing study. Clin Transl Gastroenterol. 2021;12:e00414.","journal-title":"Clin Transl Gastroenterol"},{"key":"2020_CR9","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1001\/jama.2018.6228","volume":"319","author":"C Hu","year":"2018","unstructured":"Hu C, Hart SN, Polley EC, Gnanaolivu R, Shimelis H, Lee KY, et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA. 2018;319:2401\u20139.","journal-title":"JAMA"},{"key":"2020_CR10","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1093\/jnci\/djac069","volume":"114","author":"A Gardiner","year":"2022","unstructured":"Gardiner A, Kidd J, Elias MC, Young K, Mabey B, Taherian N, et al. Pancreatic ductal carcinoma risk associated with hereditary cancer-risk genes. J Natl Cancer Inst. 2022;114:996\u20131002.","journal-title":"J Natl Cancer Inst"},{"key":"2020_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41436-019-0633-8","volume":"22","author":"H LaDuca","year":"2020","unstructured":"LaDuca H, Polley EC, Yussuf A, Hoang L, Gutierrez S, Hart SN, et al. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. Genet Med. 2020;22:407\u201315.","journal-title":"Genet Med"},{"key":"2020_CR12","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1200\/JCO.21.01604","volume":"40","author":"HL Kindler","year":"2022","unstructured":"Kindler HL, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol. 2022;40:3929\u201339.","journal-title":"J Clin Oncol"},{"key":"2020_CR13","doi-asserted-by":"publisher","first-page":"4782","DOI":"10.1158\/1078-0432.CCR-22-1483","volume":"28","author":"W Park","year":"2022","unstructured":"Park W, O\u2019Connor CA, Bandlamudi C, Forman D, Chou JF, Umeda S, et al. Clinico-genomic characterization of ATM and HRD in pancreas cancer: application for practice. Clin Cancer Res. 2022;28:4782\u201392.","journal-title":"Clin Cancer Res"},{"key":"2020_CR14","doi-asserted-by":"crossref","unstructured":"Golan T, O\u2019Kane GM, Denroche RE, Raitses-Gurevich M, Grant RC, Holter S, et al. Genomaic features and classification of homologous recombination deficient pancreatic ductal adenocarcinoma. Gastroenterology. 2021;160: 2119\u201332.","DOI":"10.1053\/j.gastro.2021.01.220"},{"key":"2020_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10689-021-00248-y","volume":"21","author":"F Lesueur","year":"2022","unstructured":"Lesueur F, Easton DF, Renault AL, Tavtigian SV, Bernstein JL, Kote-Jarai Z, et al. First international workshop of the ATM and cancer risk group (4-5 December 2019). Fam Cancer. 2022;21:211\u201327.","journal-title":"Fam Cancer"},{"issue":"6","key":"2020_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkac074","volume":"6","author":"MR Sargen","year":"2022","unstructured":"Sargen MR, Helgadottir H, Yang XR, Harland M, Hatton JN, Jones K, et al. Impact of transcript (p16\/p14ARF) alteration on cancer risk in CDKN2A germline pathogenic variant carriers. JNCI Cancer Spectr. 2022;6(6):pkac074.","journal-title":"JNCI Cancer Spectr"},{"key":"2020_CR17","first-page":"614","volume":"16","author":"V Tateo","year":"2023","unstructured":"Tateo V, Marchese PV, Mollica V, Massari F, Kurzrock R, Adashek JJ. Agnostic approvals in oncology: getting the right drug to the right patient with the right genomics. Pharm (Basel). 2023;16:614.","journal-title":"Pharm (Basel)"},{"key":"2020_CR18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/d41573-020-00015-1","volume":"19","author":"AM Looney","year":"2020","unstructured":"Looney AM, Nawaz K, Webster RM. Tumor-agnostic therapies. Nat Rev Drug Discov. 2020;19:383\u20134.","journal-title":"Nat Rev Drug Discov"},{"key":"2020_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02588-2","volume":"18","author":"P Marchetti","year":"2020","unstructured":"Marchetti P, Botticelli A, Ascierto AP, Curigliano G, Giannarelli D. Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis. J Transl Med. 2020;18:446.","journal-title":"J Transl Med"},{"key":"2020_CR20","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/humu.24152","volume":"42","author":"C Fortuno","year":"2021","unstructured":"Fortuno C, Lee K, Olivier M, Pesaran T, Mai PL, de, et al. ClinGen TP53 variant curation expert panel. Specifications of the ACMG\/AMP variant interpretation guidelines for germline TP53 variants. Hum Mutat. 2021;42:223\u201336.","journal-title":"Hum Mutat"},{"key":"2020_CR21","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1001\/jamaoncol.2021.4398","volume":"7","author":"CP Kratz","year":"2021","unstructured":"Kratz CP, Freycon C, Maxwell KN, Nichols KE, Schiffman JD, Evans DG, et al. Analysis of the Li-fraumeni spectrum based on an international germline TP53 variant data set: an international agency for research on cancer TP53 database analysis. JAMA Oncol. 2021;7:1800\u20135.","journal-title":"JAMA Oncol"},{"key":"2020_CR22","doi-asserted-by":"publisher","first-page":"e236","DOI":"10.1200\/OP.20.00678","volume":"17","author":"A Chittenden","year":"2021","unstructured":"Chittenden A, Haraldsdottir S, Ukaegbu C, Underhill-Blazey M, Gaonkar S, Uno H, et al. Implementing systematic genetic counseling and multigene germline testing for individuals with pancreatic cancer. JCO Oncol Pr. 2021;17:e236\u2013e247.","journal-title":"JCO Oncol Pr"},{"key":"2020_CR23","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00516","volume":"6","author":"ED Esplin","year":"2022","unstructured":"Esplin ED, Nielsen SM, Bristow SL, Garber JE, Hampel H, Rana HQ, et al. Universal germline genetic testing for hereditary cancer syndromes in patients with solid tumor cancer. JCO Precis Oncol. 2022;6:e2100516.","journal-title":"JCO Precis Oncol"},{"key":"2020_CR24","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jama.2017.11137","volume":"318","author":"D Mandelker","year":"2017","unstructured":"Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA. 2017;318:825\u201335.","journal-title":"JAMA"},{"key":"2020_CR25","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","volume":"7","author":"NJ Samadder","year":"2021","unstructured":"Samadder NJ, Riegert-Johnson D, Boardman L, Rhodes D, Wick M, Okuno S, et al. Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome. JAMA Oncol. 2021;7:230\u20137.","journal-title":"JAMA Oncol"},{"key":"2020_CR26","volume":"15","author":"JC Jones","year":"2023","unstructured":"Jones JC, Golafshar MA, Coston TW, Rao R, Wysokinska E, Johnson E, et al. Universal genetic testing vs. guideline-directed testing for hereditary cancer syndromes among traditionally underrepresented patients in a community oncology program. Cureus. 2023;15:e37428.","journal-title":"Cureus"},{"key":"2020_CR27","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3390\/jcm14020367","volume":"14","author":"C Blanco Abad","year":"2025","unstructured":"Blanco Abad C, Gomila Pons P, Campos Ram\u00edrez S, \u00c1lvarez Alejandro M, Torres Ram\u00f3n MI, et al. Hereditary pancreatic cancer: advances in genetic testing, early detection strategies, and personalized management. J Clin Med. 2025;14:367.","journal-title":"J Clin Med"},{"key":"2020_CR28","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1200\/JCO.22.02833","volume":"41","author":"V Subbiah","year":"2023","unstructured":"Subbiah V, Kurzrock R. Universal germline and tumor genomic testing needed to win the war against cancer: genomics is the diagnosis. J Clin Oncol. 2023;41:3100\u20133.","journal-title":"J Clin Oncol"},{"key":"2020_CR29","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/jnci\/djy024","volume":"110","author":"MA Lowery","year":"2018","unstructured":"Lowery MA, Wong W, Jordan EJ, Lee JW, Kemel Y, Vijai J, et al. Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms. J Natl Cancer Inst. 2018;110:1067\u201374.","journal-title":"J Natl Cancer Inst"},{"key":"2020_CR30","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.3390\/cancers16223779","volume":"16","author":"J Llach","year":"2024","unstructured":"Llach J, Luzko I, Earl J, Barreto E, Rodr\u00edguez-Garrote M, Lleix\u00e0 M, et al. Should we offer universal germline genetic testing to all patients with pancreatic cancer? a multicenter study. Cancers (Basel). 2024;16:3779.","journal-title":"Cancers (Basel)"},{"key":"2020_CR31","first-page":"603","volume":"17","author":"MA Tempero","year":"2019","unstructured":"Tempero MA. NCCN guidelines updates: pancreatic cancer. J Natl Compr Canc Netw. 2019;17:603\u20135.","journal-title":"J Natl Compr Canc Netw"},{"key":"2020_CR32","doi-asserted-by":"publisher","first-page":"7705","DOI":"10.1245\/s10434-024-16011-3","volume":"31","author":"HG McDonald","year":"2024","unstructured":"McDonald HG, Kennedy A, Solomon AL, Williams CM, Reagan AM, Cassim E, et al. Development of a novel protocol for germline testing in pancreatic cancer. Ann Surg Oncol. 2024;31:7705\u201312.","journal-title":"Ann Surg Oncol"},{"key":"2020_CR33","doi-asserted-by":"publisher","unstructured":"Sanoba S, Wadlow R. Universal genetic testing for pancreatic cancer : closing the gap on a missed opportunity. JCO Oncol Pract. 2025;OP2500154 https:\/\/doi.org\/10.1200\/OP-25-00154.","DOI":"10.1200\/OP-25-00154"},{"key":"2020_CR34","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1200\/JCO.18.00328","volume":"36","author":"TP Slavin","year":"2018","unstructured":"Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, et al. Identification of incidental germline mutations in patients with advanced solid tumors who underwent cell-free circulating tumor DNA sequencing. J Clin Oncol. 2018;36:3459\u201365.","journal-title":"J Clin Oncol"},{"key":"2020_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.annonc.2022.12.003","volume":"34","author":"Z Kuzbari","year":"2023","unstructured":"Kuzbari Z, Bandlamudi C, Loveday C, Garrett A, Mehine M, George A, et al. Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO precision medicine working group recommendations. Ann Oncol. 2023;34:215\u201327.","journal-title":"Ann Oncol"},{"key":"2020_CR36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10689-022-00317-w","volume":"22","author":"TL Hoffman","year":"2023","unstructured":"Hoffman TL, Kershberg H, Goff J, Holmquist KJ, Haque R, Alvarado M. Next-generation universal hereditary cancer screening: implementation of an automated hereditary cancer screening program for patients with advanced cancer undergoing tumor sequencing in a large HMO. Fam Cancer. 2023;22:225\u201335.","journal-title":"Fam Cancer"},{"key":"2020_CR37","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.semcancer.2020.08.003","volume":"79","author":"M Gentiluomo","year":"2022","unstructured":"Gentiluomo M, Canzian F, Nicolini A, Gemignani F, Landi S, Campa D. Germline genetic variability in pancreatic cancer risk and prognosis. Semin Cancer Biol. 2022;79:105\u201331.","journal-title":"Semin Cancer Biol"},{"key":"2020_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02942-5","volume":"9","author":"AP Klein","year":"2018","unstructured":"Klein AP, Wolpin BM, Risch HA, Stolzenberg-Solomon RZ, Mocci E, Zhang M, et al. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nat Commun. 2018;9:556.","journal-title":"Nat Commun"}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02020-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02020-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02020-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:15:38Z","timestamp":1788783338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02020-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2020"],"URL":"https:\/\/doi.org\/10.1038\/s41431-026-02020-1","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All patients included in this study provided written informed consent for MGPT as well as for additional exploratory research analyses. In this context, approval by an ethics committee was not required.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}